EichorEICHOR
Study identifier: NCT02506153 Synced from ClinicalTrials.gov · August 02, 2026
● Active Not Recruiting

Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery

Condition: Clinical Stage III Cutaneous Melanoma AJCC v8 · Clinical Stage IV Cutaneous Melanoma AJCC v8 · Metastatic Cutaneous Melanoma  ·  Sponsor: National Cancer Institute (NCI)

PhasePhase 3
Planned participants1301
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This randomized phase III trial studies how well pembrolizumab works compared with the current standard of care, physician/patient choice of either high-dose recombinant interferon alfa-2B or ipilimumab, in treating patients with stage III-IV melanoma that has been removed by surgery but is likely to come back or spread. High-dose recombinant interferon alfa-2B may help shrink or slow the growth of melanoma. Immunotherapy with monoclonal antibodies, such as ipilimumab and pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether pembrolizumab is more effective than the current standard of care in treating patients with melanoma.

This description comes directly from the study's public registry record.

Talk to the study team

No contact information is available for this study as per the public registry record.

Always discuss trial participation with your own doctor first.

Locations (576)

University of Alabama at Birmingham Cancer CenterBirmingham, Alabama, United States
Cancer Center at Saint Joseph'sPhoenix, Arizona, United States
Virginia G Piper Cancer Care-Del CaminoScottsdale, Arizona, United States
Banner University Medical Center - TucsonTucson, Arizona, United States
University of Arizona Cancer Center-North CampusTucson, Arizona, United States
University of Arkansas for Medical SciencesLittle Rock, Arkansas, United States
Highlands Oncology Group - RogersRogers, Arkansas, United States
Kaiser Permanente-AnaheimAnaheim, California, United States
Sutter Auburn Faith HospitalAuburn, California, United States
Kaiser Permanente-Baldwin ParkBaldwin Park, California, United States
Kaiser Permanente-BellflowerBellflower, California, United States
UC Irvine Health Cancer Center-NewportCosta Mesa, California, United States

+ 564 more locations — full list on the registry record.

Follow this study

Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.

We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →